Suppr超能文献

结肠癌缺失基因(DCC)在结直肠癌及其转移灶中持续表达。

The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases.

作者信息

Gotley D C, Reeder J A, Fawcett J, Walsh M D, Bates P, Simmons D L, Antalis T M

机构信息

University of Queensland Department of Surgery, Princess Alexandra Hospital, Brisbane, Queensland, Australia.

出版信息

Oncogene. 1996 Aug 15;13(4):787-95.

PMID:8761300
Abstract

The DCC (deleted in colorectal cancer) gene was originally identified as a candidate tumour suppressor gene in colon carcinogenesis on the basis of allelic losses in chromosome 18q.21 in 70% of colon cancers. Reverse transcriptase polymerase chain reaction (RT-PCR) of DCC mRNA suggests that DCC expression may also be reduced in colon cancers. We have used monoclonal antibodies generated against the DCC immunoglobulin-like domain to investigate DCC isoforms and DCC protein expression during colon cancer progression. Normal mucosa and colonic tumour specimens representative of the range of colonic tumour progression from benign adenomatous polyps to metastases were compared by Western blot analyses. We show that while M(r) 194 000 DCC is present in normal colonic mucosa and adenomatous polyps, it is also similarly expressed in colorectal carcinomas and colonic metastases in the liver. The presence of DCC protein is consistent with the presence of DCC mRNA transcripts in the same tissue specimens. Notably DCC was not completely lost in any colonic tumour specimens examined, even those that had progressed to metastatic cancers. Quantitation of DCC protein expression in tissue specimens by densitometry demonstrated that both normal and malignant specimens exhibit a wide range of DCC protein levels and there was no significant correlation between diminished DCC protein expression and colon cancer progression. These results demonstrate the pattern of expression of the DCC gene product in colonic tumour progression and show that absence of DCC expression is not associated with colonic tumour progression.

摘要

结直肠癌缺失基因(DCC)最初是基于70%的结肠癌中18q.21染色体上等位基因缺失,而被鉴定为结肠癌发生过程中的候选肿瘤抑制基因。对DCC信使核糖核酸(mRNA)进行逆转录聚合酶链反应(RT-PCR)表明,DCC表达在结肠癌中也可能降低。我们利用针对DCC免疫球蛋白样结构域产生的单克隆抗体,来研究结肠癌进展过程中的DCC异构体和DCC蛋白表达。通过蛋白质免疫印迹分析,比较了代表从良性腺瘤性息肉到转移瘤等一系列结肠肿瘤进展的正常黏膜和结肠肿瘤标本。我们发现,虽然分子量为194 000的DCC存在于正常结肠黏膜和腺瘤性息肉中,但在结直肠癌和肝脏中的结肠转移瘤中也有类似表达。DCC蛋白的存在与同一组织标本中DCC mRNA转录本的存在一致。值得注意的是,在所检查的任何结肠肿瘤标本中,即使是那些已经发展为转移性癌症的标本,DCC也没有完全缺失。通过光密度测定法定量组织标本中的DCC蛋白表达,结果表明正常和恶性标本均呈现出广泛的DCC蛋白水平范围,并且DCC蛋白表达降低与结肠癌进展之间没有显著相关性。这些结果证明了DCC基因产物在结肠肿瘤进展中的表达模式,并表明DCC表达缺失与结肠肿瘤进展无关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验